GRCL
Income statement / Annual
Last year (2022), Gracell Biotechnologies Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2022, Gracell Biotechnologies Inc.'s net income was -$607.51 M.
See Gracell Biotechnologies Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$366,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$366,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
1 |
0 |
0 |
0 |
| Research and Development
Expenses |
$485.39 M
|
$326.90 M
|
$168.83 M
|
$119.22 M
|
$52.24 M
|
| General & Administrative
Expenses |
$139.27 M
|
$137.04 M
|
$45.57 M
|
$27.36 M
|
$10.26 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$139.27 M
|
$137.04 M
|
$45.57 M
|
$27.36 M
|
$10.26 M
|
| Other Expenses |
$8.16 M |
$9.06 M |
$4.70 M |
$1.43 M |
$276,000.00 |
| Operating Expenses |
$624.66 M |
$463.94 M |
$214.40 M |
$146.58 M |
$62.50 M |
| Cost And Expenses |
$624.66 M |
$463.94 M |
$214.40 M |
$146.58 M |
$62.50 M |
| Interest Income |
$23.92 M |
$9.12 M |
$2.87 M |
$3.93 M |
$1.44 M |
| Interest Expense |
$6.74 M |
$5.06 M |
$2.16 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$32.08 M
|
$78.45 M
|
$7.57 M
|
$2.57 M
|
$2.99 M
|
| EBITDA |
-$592.58 M
|
-$385.13 M
|
-$206.83 M
|
-$144.01 M
|
-$57.80 M
|
| EBITDA Ratio |
0 |
-1052.26 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
-1266.59
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$17.17 M
|
$11.82 M
|
$2.50 M
|
$7.92 M
|
$1.71 M
|
| Income Before Tax |
-$607.49 M |
-$451.75 M |
-$211.90 M |
-$138.66 M |
-$60.79 M |
| Income Before Tax Ratio
|
0
|
-1234.3
|
0
|
0
|
0
|
| Income Tax Expense |
$22,000.00 |
$14.13 M |
-$14.74 M |
-$6.49 M |
$1.71 M |
| Net Income |
-$607.51 M |
-$465.88 M |
-$197.16 M |
-$132.18 M |
-$60.79 M |
| Net Income Ratio |
0 |
-1272.9 |
0 |
0 |
0 |
| EPS |
-5.65 |
-7.08 |
-3.01 |
-6.67 |
-3.07 |
| EPS Diluted |
-5.65 |
-7.08 |
-3.01 |
-6.67 |
-3.07 |
| Weighted Average Shares
Out |
$107.49 M
|
$65.77 M
|
$65.56 M
|
$19.81 M
|
$19.81 M
|
| Weighted Average Shares
Out Diluted |
$107.49 M
|
$65.77 M
|
$65.56 M
|
$19.81 M
|
$19.81 M
|
| Link |
|
|
|
|
|
